{"text": "stock bmy bristol myers squibb news pharma stocks etfs can deal with drug pricing legislation nasdaq try now the best pivot point calculator tradingview stocks stockstowatch"}
{"text": "lian bmy camzyos mavacamten more color below"}
{"text": "lian bmy on camzyos mavacamten to paraphrase over 1 400 hcps being rem certified this is probably the most important leading indicator for this product launch physicians are going to be rems certified if they have intent to use"}
{"text": "lian camzyos mavacamten bmy says we re seeing a healthy increase in the number of centers prescribing week over week we don t see any access issues on the horizon that would prevent these patients who are getting on to therapy converting to drug"}
{"text": "lian in april 2022 bms amended the terms of a license arrangement and paid a third party 295 million to extinguish a future royalty obligation related to mavacamten prior to its fda approval in april 2022 from bmy 10q"}
{"text": "sweepcast unusual options observed bmy with our scanner on 74 put expiring 07 29 2022 worth 65k start your trial today on amp follow us stockstowatch stockmarket"}
